T. Rowe Price reports 6% stake in Celldex

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Celldex Therapeutics Inc. on a Schedule 13G. The firm reported holding 4,686,187 shares of common stock, representing 6.0% of the class, with sole voting power over 4,683,226 shares and sole dispositive power over 4,686,187 shares. T. Rowe Price Associates stated that this report should not be construed as an admission that it is the beneficial owner of these securities.

Key Figures

Shares beneficially owned: 4,686,187 shares Percent of class: 6.0% Sole voting power: 4,683,226 shares +1 more

4 metrics

Shares beneficially owned 4,686,187 shares Amount beneficially owned by T. Rowe Price Associates in Celldex common stock

Percent of class 6.0% Percent of Celldex common stock class reportedly owned

Sole voting power 4,683,226 shares Shares over which T. Rowe Price Associates has sole power to vote

Sole dispositive power 4,686,187 shares Shares over which T. Rowe Price Associates has sole power to dispose

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Schedule 13G

4 terms

beneficially owned financial

"Amount beneficially owned: 4686187"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 4,683,226.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 4,686,187.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"T. Rowe Price Associates, Inc. 2 | 4 | Citizenship or Place of Organization"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Celldex Therapeutics (CLDX) does T. Rowe Price Associates own?

T. Rowe Price Associates reported beneficial ownership of 6.0% of Celldex Therapeutics’ common stock, corresponding to 4,686,187 shares, as disclosed in its Schedule 13G filing.

How many Celldex Therapeutics (CLDX) shares does T. Rowe Price Associates report holding?

T. Rowe Price Associates reported 4,686,187 shares of Celldex Therapeutics common stock, with 4,683,226 shares having sole voting power and 4,686,187 shares having sole dispositive power.

Does T. Rowe Price Associates claim beneficial ownership of CLDX shares?

T. Rowe Price Associates expressly denies beneficial ownership in its statement, noting that the filing should not be construed as an admission that it is the beneficial owner of the Celldex Therapeutics securities.

What type of securities in Celldex Therapeutics (CLDX) are held by T. Rowe Price Associates?

The position reported by T. Rowe Price Associates consists of common stock of Celldex Therapeutics Inc., identified by CUSIP 15117B202, according to the Schedule 13G.

Where is T. Rowe Price Associates, the CLDX Schedule 13G filer, organized and located?

T. Rowe Price Associates is organized in Maryland and lists its principal business office at 1307 Point Street, Baltimore, MD 21231 in the Schedule 13G filing for Celldex Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:39 AM Accepted by SEC EDGAR 08/14/2026 - 10:38 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

CELLDEX THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

15117B202

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 15117B202

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,683,226.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,686,187.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,686,187.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CELLDEX THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 15117B202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4686187
(b)	Percent of class: 6.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4683226
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4686187
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026